Ferry D et al. - As shown in the current study,  gemcitabine in combination with carboplatin was not inferior to cisplatin with respect to survival in patients with advanced NSCLC. Carboplatin was associated with more adverse events and a poorer quality of life. 

Methods
1363 patients with chemo-naïve stage IIIB/IV NSCLC received gemcitabine (1250 mg/m2 on days 1 and 8 of a 3-week cycle) with cisplatin (80 mg/m2 [GC80]) or cisplatin (50 mg/m2 [GC50]) or carboplatin AUC6 (GCb6) for a maximum of 4 cycles.
The primary outcome measure was survival time.
The secondary outcome measures included response rate, adverse events and quality of life.

Results
Median survival times were as follows: GC50, 8.2 months compared to 9.5 for GC80 and 10.0 for GCb6.
HRs for GC50 compared to GC80 was 1.13 and for GC50 compared to GCb6 was 1.23.
GCb6 was non-inferior to GC80 (HR = 0.93).
The objective response rates were 29% (GC80), 20% (GC50), and 27% (GCb6).